709 related articles for article (PubMed ID: 28569920)
1. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
[TBL] [Abstract][Full Text] [Related]
2. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
[TBL] [Abstract][Full Text] [Related]
3. Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
Alenazy FO; Harbi MH; Kavanagh DP; Price J; Brady P; Hargreaves O; Harrison P; Slater A; Tiwari A; Nicolson PLR; Connolly DL; Kirchhof P; Kalia N; Jandrot-Perrus M; Mangin PH; Watson SP; Thomas MR
J Thromb Haemost; 2023 Nov; 21(11):3236-3251. PubMed ID: 37541591
[TBL] [Abstract][Full Text] [Related]
4. Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies.
Jamasbi J; Megens RT; Bianchini M; Münch G; Ungerer M; Faussner A; Sherman S; Walker A; Goyal P; Jung S; Brandl R; Weber C; Lorenz R; Farndale R; Elia N; Siess W
J Am Coll Cardiol; 2015 Jun; 65(22):2404-15. PubMed ID: 26046734
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
6. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin.
Ahmed MU; Kaneva V; Loyau S; Nechipurenko D; Receveur N; Le Bris M; Janus-Bell E; Didelot M; Rauch A; Susen S; Chakfé N; Lanza F; Gardiner EE; Andrews RK; Panteleev M; Gachet C; Jandrot-Perrus M; Mangin PH
Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2127-2142. PubMed ID: 32698684
[TBL] [Abstract][Full Text] [Related]
8. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
Kottke-Marchant K; Powers JB; Brooks L; Kundu S; Christie DJ
Clin Appl Thromb Hemost; 1999 Apr; 5(2):122-30. PubMed ID: 10725993
[TBL] [Abstract][Full Text] [Related]
9. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
Chang CH; Chung CH; Tu YS; Tsai CC; Hsu CC; Peng HC; Tseng YJ; Huang TF
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1307-1314. PubMed ID: 28596377
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
11. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
12. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
[TBL] [Abstract][Full Text] [Related]
13. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
15. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments.
Lecut C; Feeney LA; Kingsbury G; Hopkins J; Lanza F; Gachet C; Villeval JL; Jandrot-Perrus M
J Thromb Haemost; 2003 Dec; 1(12):2653-62. PubMed ID: 14675102
[TBL] [Abstract][Full Text] [Related]
16. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization.
Matsumoto Y; Takizawa H; Gong X; Le S; Lockyer S; Okuyama K; Tanaka M; Yoshitake M; Tandon NN; Kambayashi J
Thromb Res; 2007; 119(3):319-29. PubMed ID: 16566959
[TBL] [Abstract][Full Text] [Related]
17. Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin.
Ebrahim M; Jamasbi J; Adler K; Megens RTA; M'Bengue Y; Blanchet X; Uhland K; Ungerer M; Brandl R; Weber C; Elia N; Lorenz R; Münch G; Siess W
Thromb Haemost; 2018 Feb; 118(2):351-361. PubMed ID: 29378359
[TBL] [Abstract][Full Text] [Related]
18. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
Abulencia JP; Tien N; McCarty OJ; Plymire D; Mousa SA; Konstantopoulos K
Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):149-56. PubMed ID: 11145947
[TBL] [Abstract][Full Text] [Related]
19. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
Sugidachi A; Ohno K; Ogawa T; Jakubowski J; Hashimoto M; Tomizawa A
Br J Pharmacol; 2013 May; 169(1):82-9. PubMed ID: 23347039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
